Skip to main content
TDR: For Research on Diseases of Poverty

Access

  • Home Alt+0
  • Navigation Alt+1
  • Content Alt+2

Navigation

  • Home
  • About us
  • Research
  • Capacity building
  • Grants
  • Publications
    & resources
  • Partnerships
    & networks
  • Diseases
    & topics
  • News
    & events

Research on neglected priority needs, including product R&D, evaluation in real life settings, and increasing access to new tools

Developing research leadership through education, training, networks and quality management

Assessing global research needs and priorities, providing knowledge management and support for partner coordination

All the calls for research and training grants, career development fellowships and how to apply

Read, download or order TDR's publications and multimedia resources

For the latest news, press releases and TDR events

For more on TDR's strategy, governance, history and to find our staff

For more on TDR partnerships and networks

Search

Advanced search

Subnavigation

  • Publications & resources
  • Research and training
  • TDRnews
  • About TDR
    • TDR reports
  • Peer-reviewed articles
  • Journal supplements
  • Videos
    • Completed productions
    • Video bites (B-roll)
    • Public service announcements

Assessment of the safety of artemisinin compounds in pregnancy

Report of the two informal consultations convened by WHO in 2002 (Roll Back Malaria and the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases)

Share
Email Twitter Facebook Google Delicious LinkedIn
More...
Print

Publication details

Publication date: 2003
WHO reference number: WHO/RBM/TDR/Artemisinin/03.1
Number of pages: 22
Languages: English

Downloads

  • English
    pdf, 197kb

Summary

Various artemisinin compounds have been used as treatment for different forms of malaria since the early 1980s, initially in China, where they were first developed, and subsequently in many other countries. The literature on their use in pregnancy has been limited and animal studies have suggested that their use in pregnancy be restricted. With the increasing amount of interest in artemisinin combinations and artemisinin compounds in general, more studies - preclinical and clinical - are being envisaged and have been undertaken. 

With more data becoming available it was time to re-evaluate existing data and policies on the use of artemisinin compounds in pregnancy. The 2000 WHO recommendations were reviewed in two consultations in 2002. This report presents WHO’s current position on use of artemisinin compounds during pregnancy.

You are here:

  • TDR
  • Publications & resources
  • Research and training publications
  • © WHO 2013
  • More about our sponsors
  • Contact us

Special Programme for Research and Training in Tropical Diseases (TDR)